Icade Management
Management Kriterienprüfungen 3/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Nicolas Joly
Geschäftsführender
€836.0k
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 53.83% |
| Amtszeit als Geschäftsführer | 3.3yrs |
| Eigentum des Geschäftsführers | n/a |
| Durchschnittliche Amtszeit des Managements | 6yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.3yrs |
Jüngste Management Updates
Recent updates
Narrative-Update • Jun 22
ICAD: Cautious Outlook And Special Meeting Timing Will Shape Balanced Future
Analysts have nudged their fair value estimate for Icade from €21.31 to €21.67, reflecting a slightly higher €22 price target and a view that the stock now presents more limited downside at current levels. What’s in the News for Icade Icade has scheduled a Special and Extraordinary Shareholders Meeting for June 10, 2026.
Narrative-Update • Jun 06
ICAD: Limited Downside View Will Still Pressure Shares Going Forward
Analysts have raised their fair value estimate for Icade from €16.30 to €17.00, citing a higher Street price target of €22 and the view that downside risk at current levels now appears more limited. What's in the News Icade has scheduled a Special and Extraordinary Shareholders Meeting for June 10, 2026, at the Coeur Defense building, Tour B Espace Comet, 24th floor, 100 Esplanade du General de Gaulle, Paris La Defense Cedex, France.Narrative-Update • May 22
ICAD: Slower Healthcare Exit And Paused Special Payouts Will Shape Balanced Outlook
Analysts have nudged their fair value estimate for Icade slightly lower to about €21.31. This reflects a reduced price target and updated assumptions around slower revenue growth, a modestly softer profit margin, a higher discount rate and the view that asset disposals and potential special dividends may take longer to materialise.Narrative-Update • May 06
ICAD: Slower Healthcare Disposal And Halted Special Payouts Will Pressure Shares
Analysts have reduced their price target on Icade from €30 to €25, citing expectations that the healthcare business disposal could take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts are flagging a more cautious stance on Icade, with recent research pointing to timing and payout uncertainties that weigh on sentiment.Narrative-Update • Apr 21
ICAD: Slower Healthcare Disposal And Lost Special Dividends Will Pressure Shares
Analysts have trimmed their price target for Icade to €25 from €30, reflecting expectations that the planned disposal of the healthcare business may take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts have shifted to a more cautious stance on Icade, with the rating cut to Equal Weight from Overweight and the price target moved to €25 from €30.Narrative-Update • Apr 06
ICAD: Slower Healthcare Disposal And Missing Special Dividends Will Shape Fair Outlook
Narrative Update The analyst price target for Icade has been trimmed to €21.35 from €21.54. This reflects a more cautious stance from analysts after recent downgrades and expectations that healthcare asset disposals and potential special dividends may take longer to play out.
Narrative-Update • Mar 23
ICAD: Slower Healthcare Exit And Reset Distributions Will Support Future Repricing
Analysts have trimmed their fair value estimate for Icade to about €29.91 from €31.29, echoing recent price target cuts, such as the move from €30 to €25, as they factor in a longer timeline for healthcare asset disposals and the absence of expected special dividends. Analyst Commentary The recent research updates on Icade point to a more cautious stance as analysts reassess how quickly the group can execute on its healthcare disposals and how generous future shareholder returns might be.Narrative-Update • Mar 08
ICAD: Slower Healthcare Disposals And Lost Special Dividends Will Shape Fairly Valued Outlook
Analysts have modestly trimmed their fair value estimate for Icade from €22.03 to about €21.54. This reflects updated views on slower progress on healthcare disposals, a higher required discount rate and the removal of assumed special dividends after recent downgrades and price target cuts on the stock.Narrative-Update • Feb 22
ICAD: Higher Office Risk Premium Will Set Stage For Future Repricing
Analysts have reduced their fair value estimate for Icade from about €36.67 to about €31.29, reflecting a higher assumed discount rate and lower profit margin expectations following recent rating cuts and a lower €18 Street price target. Analyst Commentary Recent rating actions on Icade have leaned cautious, with cuts to both recommendations and price targets that feed into the lower fair value estimate.Narrative-Update • Feb 08
ICAD: Office Risk Repricing And Downgrades Will Shape Fairly Valued Outlook
Analysts have trimmed their fair value estimate for Icade from €23.33 to €22.03. This reflects a slightly higher discount rate, a modestly lower profit margin outlook and recent downgrades that cite a higher perceived equity risk premium in offices.Narrative-Update • Jan 24
ICAD: Office Risk Repricing And Downgrades Will Shape Future Share Performance
Analysts have trimmed their fair value estimate for Icade from about €23.46 to roughly €23.33, citing slightly higher required returns, more cautious assumptions on revenue growth and profit margins, and recent Street downgrades, including a cut in one price target from €25 to €18. Analyst Commentary Bullish Takeaways Bullish analysts may see the recent pullback in fair value and price targets as already reflecting higher equity risk premiums in offices, which can limit further downside if execution on existing projects is steady.Narrative-Update • Jan 10
ICAD: Office Downgrades And Higher Risk Premium Will Pressure Shares
Analysts have trimmed their price expectations for Icade to around €14.60, reflecting recent rating downgrades and a higher equity risk premium for office assets. This has been incorporated into updated assumptions for revenue growth, profit margins and future P/E levels.Narrative-Update • Dec 26
ICAD: Office Risk Repricing Will Shape Margins And Share Performance
Analysts have lowered their price target on Icade from EUR 25 to EUR 18. This reflects a higher perceived equity risk in offices, alongside slightly faster expected revenue growth but weaker profit margins and a higher valuation multiple.Narrative-Update • Dec 12
ICAD: Office Weakness And Higher Equity Risk Will Pressure Shares
Analysts have cut their price target on Icade from EUR 17.80 to EUR 14.60, reflecting a lower revenue growth outlook and higher perceived equity risk in offices, even as profit margins are expected to improve. Analyst Commentary Bearish analysts have recently shifted their stance on Icade, highlighting a weaker outlook for office assets and increasing caution around the company’s equity risk profile.
Neues Narrative • Apr 28
Pulse Building Lease With Seine-Saint-Denis Will Boost Portfolio Strength
Improved rental growth expected from the lease agreement and focus on prime locations may enhance revenue stability.Analyseartikel • Feb 23
A Look At Icade's (EPA:ICAD) Share Price Returns
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...Analyseartikel • Jan 19
How Did Icade SA's (EPA:ICAD) 8.0% ROE Fare Against The Industry?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Dec 31 2025 | €836k | €450k | -€123m |
| Sep 30 2025 | n/a | n/a | -€155m |
| Jun 30 2025 | n/a | n/a | -€187m |
| Mar 31 2025 | n/a | n/a | -€231m |
| Dec 31 2024 | €805k | €450k | -€275m |
| Sep 30 2024 | n/a | n/a | -€614m |
| Jun 30 2024 | n/a | n/a | -€953m |
| Mar 31 2024 | n/a | n/a | -€1b |
| Dec 31 2023 | €728k | €311k | -€1b |
Vergütung im Vergleich zum Markt: NicolasDie Gesamtvergütung ($USD954.23K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt French ($USD1.61M).
Entschädigung vs. Einkommen: NicolasDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Nicolas Joly (43 yo)
3.3yrs
Amtszeit
€836,000
Vergütung
Mr. Nicolas Joly has been Chief Executive Officer of Icade since April 21, 2023. Mr. Joly served as Deputy Director-General at Mercialys and had been its Executive Vice-President since 2016. Mr. Joly joine...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chief Executive Officer | 3.3yrs | €836.00k | keine Daten | |
| Chief Financial Officer | 1.3yrs | keine Daten | keine Daten | |
| Head of Consolidation & Accounting | no data | keine Daten | keine Daten | |
| Head of Corporate Finance and Director of Financing & Investor Relations | 3.5yrs | keine Daten | keine Daten | |
| General Secretary and Head of Governance | 10.8yrs | keine Daten | keine Daten | |
| Head of Audit | 8.5yrs | keine Daten | keine Daten | |
| Head of Communications & Public Affairs | no data | keine Daten | keine Daten | |
| Head of Human Resources & Work Environment | no data | keine Daten | keine Daten | |
| Head of the Commercial Property Investment Division | 10.8yrs | keine Daten | keine Daten | |
| Head of Financial Control | no data | keine Daten | keine Daten | |
| Head of Asset Management | no data | keine Daten | keine Daten | |
| Head of Sustainable Development | no data | keine Daten | keine Daten |
6.0yrs
Durchschnittliche Betriebszugehörigkeit
55yo
Durchschnittliches Alter
Erfahrenes Management: Das Managementteam von ICAD ist erfahren und erfahren (durchschnittliche Amtszeit von 6 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Director | 5.8yrs | €28.00k | 0% € 0 | |
| Independent Director | 2.6yrs | €24.50k | 0.00033% € 4.7k | |
| Independent Director | 2.3yrs | €45.50k | 0.00082% € 11.6k | |
| Independent Director | 7.3yrs | €22.75k | 0.00011% € 1.6k | |
| Chairman of the Board | 10.2yrs | €240.00k | 0.000040% € 565.4 | |
| Director | 15.2yrs | keine Daten | 0% € 0 | |
| Director | 6.8yrs | keine Daten | 0% € 0 | |
| Vice Chairman of the Board & Lead Independent Director | 10.2yrs | €99.50k | 0.00067% € 9.5k | |
| Independent Director | 2.8yrs | €56.00k | 0.0013% € 18.7k | |
| Director | 1.4yrs | keine Daten | 0% € 0 | |
| Director | 2.8yrs | keine Daten | 0% € 0 | |
| Director | 1.4yrs | keine Daten | 0% € 0 |
4.3yrs
Durchschnittliche Betriebszugehörigkeit
61yo
Durchschnittliches Alter
Erfahrener Vorstand: ICADDie Vorstandsmitglieder gelten als erfahren (4.3 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/13 16:27 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Icade wird von 18 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Celine Huynh | Barclays |
| Paul May | Barclays |
| Aaron Guy | Barclays |